PDF(Pubmed)
Abstract：
GLP-1 receptor agonists (GLP-1 RA) are presently used as the first-line drugs for the clinical treatment of type 2 diabetes mellitus (T2DM). It can regulate blood glucose by stimulating insulin secretion and lowering glucagon levels. We used 16S rRNA amplicon sequencing to detect structural changes in the composition of the intestinal flora of newly diagnosed T2DM after 1 and 48 weeks of dulaglutide administration. Our research found no significant changes in the intestinal flora after the administration of dulaglutide for 1 week to subjects with newly diagnosed T2DM. Nevertheless, after 48 weeks of dulaglutide administration, the composition of the intestinal flora changed significantly, with a significant reduction in the abundance of intestinal flora. Furthermore, we found that fasting glucose levels, fasting c-peptide levels, HbA1c levels, and BMI are also closely associated with intestinal flora. This reveals that intestinal flora may be one of the mechanisms by which dulaglutide treats T2DM.
摘要：
GLP-1受体激动剂(GLP-1RA)是目前临床治疗2型糖尿病(T2DM)的一线药物。它可以通过刺激胰岛素分泌和降低胰高血糖素水平来调节血糖。我们使用16SrRNA扩增子测序来检测在杜拉鲁肽给药1和48周后新诊断的T2DM的肠道菌群组成的结构变化。我们的研究发现，在对新诊断的T2DM受试者服用杜拉鲁肽1周后，肠道菌群没有显着变化。然而，杜拉鲁肽给药48周后，肠道菌群的组成发生了显著变化,肠道菌群丰度显著降低。此外，我们发现空腹血糖水平,空腹C肽水平，HbA1c水平,BMI也与肠道菌群密切相关。这表明肠道菌群可能是杜拉鲁肽治疗T2DM的机制之一。
